Farmácia anuncia parceria com Oxford para comercializar atualizados múltiplas vacinas variantes contra imunizantes, baseado na estratégia. Autorização, introdução no mercado e declínio de antigas vacinas em andamento. Autorizações para comercialização em curso para novos imunizantes.
A vacina da AstraZeneca foi retirada de circulação em escala global, produzida em colaboração com a Universidade de Oxford (Inglaterra).
O processo de imunização com a AstraZeneca é fundamental no combate à Covid-19, pois a vaccine tem desempenhado um papel crucial na proteção da população contra o vírus e na diminuição da propagação da doença de forma significativa.
AstraZeneca to Retire Vaxzevria Vaccine from the Market
The decision to withdraw the AstraZeneca’s Vaxzevria vaccine against Covid-19 has officially begun in the European Union. This move came into effect on Tuesday (7). The pharmaceutical company had previously requested the voluntary withdrawal of its ‘authorization for market introduction’ on March 5, as reported by The Telegraph.
In the upcoming months, AstraZeneca will extend this request to all other countries where the vaccine had been approved, except in the United States where its application was not approved by the FDA. Consequently, no individual will be vaccinated with this particular immunization anymore, which has been credited with saving over six million lives.
Motivations for AstraZeneca’s decision to pull the Covid-19 vaccine from the market are primarily commercial. The company stated that the Vaxzevria vaccine is no longer in production or distribution and has been replaced by newer and updated vaccines capable of addressing more recent variants. AstraZeneca expressed pride in the role that the Vaxzevria had played in the global pandemic’s conclusion.
As multiple updated vaccines for Covid-19 have been developed since, leading to a wane in demand for Vaxzevria, the company opted to initiate the withdrawal of market introductions of Vaxzevria in Europe. AstraZeneca emphasized collaborating with regulators and partners to align on a clear path to conclude this chapter and significantly contribute to the Covid-19 pandemic.
It was further stated that a partnership with regulatory authorities worldwide would be established to withdraw the marketing authorization of Vaxzevria wherever there is no future commercial demand for the vaccine.
Unwinding of Vaccination Authorizations
The withdrawal of the anti-Covid Vaxzevria vaccine from AstraZeneca is now officially in motion, in alignment with the expectation that unused and updated vaccines will be phased out. Marco Cavaleri, head of vaccines at the European Medicines Agency, the body responsible for drug and vaccine safety in the EU, conveyed to the Italian press that he anticipates all monovalent vaccines, targeting only the original strain of SARS-CoV-2, to be removed promptly.
Fonte: @Olhar Digital
Comentários sobre este artigo